No Data
No Data
Viva Biotech Plans Board Meeting for Financial Review
Viva Biotech (01873.HK) plans to hold a board of directors meeting on August 29 to approve its mid-year performance.
Viva Biotech (01873.HK) announced that the company will hold a board of directors meeting on Thursday, August 29, 2024 to consider and approve the company's and its affiliates' six-month interim performance ending on June 30, 2024 and its release, and to consider recommending the payment of interim dividends (if any).
VIVA BIOTECH: DATE OF BOARD MEETING
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
No Data